miRNA in diagnosis, monitoring, and progression of RCC
miRNA | Sample | Expression | Comments | Reference | |
---|---|---|---|---|---|
miR in RCC diagnosis | |||||
miR-210/miR-210-3p | Urine | Up-regulated | Expressed in response to hypoxia mainly through HIF-1α, a key player of renal carcinogenesis miR-210 overexpression directly targets HIF-1α expression and suppresses the HIF-1α pathway activation, thereby significantly attenuating the hypoxia induced renal tubular cell apoptosis | [58, 59] | |
miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429 | Urine and serum | Down-regulated | Act as tumor suppressors markers Involved in the regulation of EMT, tumor metastasis, tumor stemness maintenance, and chemotherapy resistance process in cancer development | [33, 60, 61] | |
miR-15a | Biopsy and urine samples | Up-regulated | Apoptosis and cell proliferation Promotes proliferation, invasion, migration, and epithelial mesenchymal transition of ccRCC cells Accelerates RCC cell viability by downregulating BTG2 and promoting the activity of the P13K/AKTsignalling pathway | [50, 62] | |
miR-30c-5p | Urine exosomes | Down-regulated | Modulates the expression of HSPA5 which is correlated with the progression of ccRCC Associated with increased HIF-2α activity promoting epithelial mesenchymal transition in ccRCC | [63, 64] | |
miR-497 | Tissues, blood, and urine | Down-regulated | Involved in processes like inflammatory responses, malignant behavior of tumors, and epithelial-mesenchymal transformation Regulates proliferation of ccRCC via up-regulation of IL-6R | [65] | |
miR-204-5p | Urinary exosomes | Down-regulated | Acts as a tumor suppressor which suppresses RCC proliferation and invasion by targeting the RABB22A gene | [66, 67] | |
miR-200a-3p/miR-34a-5p/miR-365a-3p | Urine | Down-Regulated | - | [68] | |
miR-28/miR-125/miR-27/miR-let-7f-2 | Tissue | Up-regulated | Induced cell mobility and inhibited apoptosis | [69] | |
miRNA in RCC monitoring | |||||
miR-210-3p | Urine | Down-regulated in RCC follow up samples post treatment | Up-regulated miR-210 in RCC promotes cell proliferation and tumorigenesis through the epithelial mesenchymal transition pathway by targeting the TWIST1 gene | [69, 70] | |
miR-let-7d-5p/miR-152-3p/miR-30c-5p/miR-362-3p/miR-30e-3p | Urine | Down-regulated post-surgery | - | [68] | |
miRNA in RCC prognosis | |||||
miR-221 | Plasma | Up-regulated | Enhances tumor cell proliferation through the angiogenesis pathway Co-related with lower OS rate in patients with metastasis Promotes cell proliferation, and mobility and inhibits cell apoptosis in 786-O and ACHN cell lines | [69, 71, 72] | |
miR-122-5p/miR-206 | Serum | Up-regulated | Reduced period of progression free, cancer specific, and OS in ccRCC patients | [51] | |
miR-149 | Plasma, serum, and urine | Down-regulated | Loss of miR-149 is linked to the gain of function of the KCNMAI and LOX | [56] | |
miR-9-1, miR-9-2, miR-18a, miR-21, miR-130b, miR-146b, miR-149, miR-183, miR-223, miR-335, miR-365-1, miR-365-2 and miR-625 | Plasma, serum, and urine | - | Associated with worse tumor stages and elevated tumor re-occurrence | [54] |
EMT: epithelial and mesenchymal transition; HSPA5: heat shock protein 5; KCNMAI: oncogenes potassium calcium-activated channelsubfamily m alpha 1; LOX: lysyl oxidase; -: blank sell
The authors are grateful to the Department of Biotechnology, Himachal Pradesh University, Shimla, for the providing various resources. We are also thankful to the Department of Biotechnology, Government of India, for providing the necessary support to the authors.
SG: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. SSK: Validation, Supervision.
The authors declare that there are no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.